DaVita Receives National Award for Patient Safety Efforts
Renal Physicians Association recognizes innovative clinical practices
NEW ORLEANS -- March 18, 2013
On March 15, DaVita®, a division of DaVita HealthCare Partners Inc. (NYSE:
DVA) and a leading provider of kidney care services, was recognized with the
Patient Safety Improvement Award during the Renal Physician Association’s
(RPA) annual meeting for the company’s innovative CathAway^TM program.
Each year RPA acknowledges a pioneering initiative to improve the safety of
patients with end-stage renal disease. Awardees are selected by a committee of
physicians, patients and health care professionals.
Dialysis requires access to the patient’s vascular system, and some access
methods are more prone to infection than others. CathAway’s mission is
straightforward: eliminate infection-prone central venous catheters (CVCs) and
replace them with functioning arteriovenous (AV) fistulas or grafts for safe
and effective dialysis treatments.
Since its inception in 2008, nearly 12,000 fewer DaVita patients are dialyzing
“We’re so pleased with CathAway’s outcomes and how we’ve been able to help
improve the quality of life of thousands of patients,” said DaVita Chief
Medical Officer Allen R. Nissenson, M.D., F.A.C.P., who accepted the award on
behalf of DaVita. “By decreasing CVC use, we have also helped patients avoid
serious complications, including infection, which often result in
hospitalization and contribute to mortality.Not only are the clinical
benefits of CVC elimination substantial, but the total costs of health care
are decreased—a significant savings to taxpayers.”
DaVita’s clinical team also instituted a series of efforts to keep patients
from reverting to CVCs because of thrombosis (clotting) while dialyzing with
fistulas and grafts. These efforts included emphasizing the link between
clinical goals and patient safety in both internal and external
communications; reaching out to physicians through educational seminars that
include CathAway information; companywide engagement to encourage patients and
clinical staff to listen for signs of distress in their dialysis access; and a
pilot test of software for monitoring thrombosis risk.
The CathAway program has been extraordinarily successful. By the end of 2012
the rate of patients on dialysis for more than 90 days with a CVC dropped to
an all-time low of 13.9 percent. Clot rates dropped from 42 percent to 12
percent in the pilot surveillance program.
DaVita and DaVita HealthCare Partners are trademarks or registered trademarks
of DaVita Healthcare Partners Inc. All other trademarks are the property of
their respective owners.
DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune
500® company that, through its operating divisions, provides a variety of
health care services to patient populations throughout the United States and
abroad. A leading provider of kidney care in the United States, DaVita
delivers dialysis services to patients with chronic kidney failure and end
stage renal disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services. As of Dec.
31, 2012, DaVita operated or provided administrative services at 1,954
outpatient dialysis centers located in the United States serving approximately
153,000 patients. The company also operated 36 outpatient dialysis centers
located in eight countries outside the United States. DaVita supports numerous
programs dedicated to creating positive, sustainable change in communities
around the world. The company’s leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit DaVita.com.
David Tauchen, 303-876-2802
Press spacebar to pause and continue. Press esc to stop.